Haemonetics Corporation (HAE)
Profitability ratios
Return on sales
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 26.64% | 27.71% | 27.27% | 26.97% | 26.48% | 53.42% | 53.81% | 53.38% | 51.19% | 47.24% | 46.26% | 45.96% | 46.15% | 48.67% | 48.53% | 48.56% | 48.95% | 48.18% | 47.04% | 46.03% |
| Operating profit margin | 6.35% | 7.02% | 7.00% | 7.54% | 6.72% | 12.56% | 12.39% | 10.89% | 8.18% | 4.23% | 4.83% | 8.78% | 10.41% | 15.51% | 15.25% | 13.59% | 10.44% | 10.11% | 8.96% | 6.64% |
| Pretax margin | 5.85% | 6.64% | 6.65% | 7.06% | 6.09% | 11.14% | 10.60% | 9.11% | 6.44% | 2.19% | 2.88% | 6.84% | 8.46% | 13.85% | 13.61% | 11.95% | 8.80% | 8.70% | 4.85% | 2.65% |
| Net profit margin | 4.53% | 5.22% | 5.36% | 5.75% | 4.97% | 8.59% | 8.05% | 6.70% | 4.39% | 2.37% | 3.34% | 7.13% | 9.22% | 12.25% | 11.78% | 10.12% | 7.73% | 7.97% | 4.18% | 2.31% |
Haemonetics Corporation's profitability ratios have shown fluctuations over the past few quarters.
The Gross profit margin has been relatively stable around the mid to high 20% range, with a significant decrease observed in the last quarter of 2022.
The Operating profit margin has shown more variability, with a peak in the second quarter of 2020 followed by a steady decline until the second quarter of 2023, where an increase was recorded.
The Pretax margin also exhibits variability, with fluctuations seen in each quarter. The trend shows a decline in margins from the fourth quarter of 2020 to the second quarter of 2022, followed by an increasing trend.
The Net profit margin follows a similar pattern to the other profitability ratios, showing fluctuations and a slight uptrend from the lows of the first and second quarters of 2021.
Overall, Haemonetics Corporation has demonstrated some volatility in its profitability margins, with varying levels of performance in gross, operating, pre-tax, and net profit margins over the observed period.
Return on investment
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 7.51% | 7.73% | 8.33% | 9.12% | 8.06% | 7.45% | 7.10% | 6.05% | 4.34% | 2.20% | 2.51% | 4.43% | 4.93% | 10.39% | 9.69% | 8.96% | 8.16% | 8.18% | 7.44% | 5.16% |
| Return on assets (ROA) | 5.35% | 5.75% | 6.38% | 6.96% | 5.96% | 5.10% | 4.61% | 3.72% | 2.33% | 1.23% | 1.73% | 3.59% | 4.37% | 8.20% | 7.48% | 6.67% | 6.04% | 6.44% | 3.47% | 1.79% |
| Return on total capital | 9.38% | 9.45% | 10.20% | 11.07% | 9.93% | 9.13% | 8.89% | 7.18% | 6.17% | 2.96% | 3.23% | 5.50% | 6.31% | 13.53% | 14.24% | 14.18% | 11.58% | 11.44% | 9.87% | 7.14% |
| Return on equity (ROE) | 12.25% | 13.42% | 14.35% | 15.79% | 14.11% | 12.34% | 11.80% | 8.79% | 5.79% | 3.09% | 4.47% | 9.52% | 10.86% | 15.04% | 15.89% | 15.70% | 13.03% | 13.88% | 7.09% | 3.82% |
Haemonetics Corporation's profitability ratios exhibit a generally positive trend over the periods analyzed. The Operating Return on Assets (Operating ROA) shows a fluctuating pattern, ranging from 2.20% to 9.12%, with a recent value of 7.51% as of March 31, 2024. The Return on Assets (ROA) demonstrates a similar fluctuation, varying between 1.23% and 6.96%, with the latest figure at 5.35%. The Return on Total Capital and Return on Equity (ROE) also display an upward trend, with ROE peaking at 15.79% on March 31, 2024. Overall, the company's profitability metrics have shown improvement, albeit with some fluctuations, reflecting Haemonetics' ability to generate returns from its assets and capital.